0UGB Stock Overview
A specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
COSCIENS Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$8.70 |
| 52 Week High | CA$10.05 |
| 52 Week Low | CA$5.90 |
| Beta | 2.26 |
| 11 Month Change | 8.48% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0UGB | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 14.9% | 0.8% | 2.4% |
| 1Y | n/a | -18.7% | 11.8% |
Return vs Industry: Insufficient data to determine how 0UGB performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0UGB performed against the UK Market.
Price Volatility
| 0UGB volatility | |
|---|---|
| 0UGB Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.8% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0UGB's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0UGB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Gilles Gagnon | www.cosciensbio.com |
COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease.
COSCIENS Biopharma Inc. Fundamentals Summary
| 0UGB fundamental statistics | |
|---|---|
| Market cap | CA$25.86m |
| Earnings (TTM) | -CA$25.02m |
| Revenue (TTM) | CA$6.75m |
3.8x
P/S Ratio-1.0x
P/E RatioIs 0UGB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0UGB income statement (TTM) | |
|---|---|
| Revenue | US$4.92m |
| Cost of Revenue | US$901.00k |
| Gross Profit | US$4.01m |
| Other Expenses | US$22.24m |
| Earnings | -US$18.23m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.85 |
| Gross Margin | 81.67% |
| Net Profit Margin | -370.91% |
| Debt/Equity Ratio | 0% |
How did 0UGB perform over the long term?
See historical performance and comparison